Claims for Patent: 12,016,857

Summary for Patent: 12,016,857

Title:	Stable liquid vigabatrin pharmaceutical composition for oral dosage
Abstract:	This disclosure relates to pharmaceutical compositions in the form of a solution for oral delivery. Particularly, the pharmaceutical compositions comprise an active pharmaceutical ingredient, a buffering agent, and water. In some embodiments, the pH of the composition is from about pH 5 to about pH 8. In some embodiments, the active pharmaceutical ingredient is selected from ramipril, solifenacin, vigabatrin, losartan potassium, warfarin, and melatonin.
Inventor(s):	Sandip Mehta, Manish Kumar Umrethia, Jayanta Mandal
Assignee:	Liqmeds Worldwide Ltd
Application Number:	US18/311,126
Patent Claims:	1. A liquid pharmaceutical composition consisting of the following ingredients: a therapeutically effective amount of vigabatrin, or a pharmaceutically acceptable salt thereof, wherein the vigabatrin is present in the composition in the range from 0.1 wt % to 20 wt %; a preservative; a buffering agent; a sweetener; a flavoring agent; at least one of a solubilizer, a co-solvent, an antioxidant, a surfactant, an antifoaming agent, a chelating agent, a suspending agent, a viscosity builder, and a coloring agent; and quantum sufficit (qs.) water; wherein the liquid pharmaceutical composition is stable up to 3 months at room temperature with total impurities up to 3 months being less than 0.06%; wherein the total impurities are defined as the sum of any components that are not initially present in the composition at time 0 but that are present in the composition at up to 3 months. 2. The liquid pharmaceutical composition of claim 1, wherein the vigabatrin is present in an amount from 5 wt % to 15 wt % in the composition; the preservative is methyl 4-hydroxy benzoate, propyl 4-hydroxy benzoate, or a combination thereof; the buffering agent is sodium dihydrogen phosphate dihydrate, disodium hydrogen phosphate dihydrate, or a combination thereof; the sweetener is maltitol, sucralose, or a combination thereof; and the flavoring agent is selected from the group consisting of: synthetic flavor oils, flavoring aromatics, plant leave extracts, flower extracts, fruit extracts, cinnamon oil, oil of wintergreen, peppermint oils, clove oil, bay oil, anise oil, eucalyptus, thyme oil, cedar leaf oil, oil of nutmeg, oil of sage, oil of bitter almonds, cassia oil, vanilla, citrus oil, fruit essence tutti-fruity flavor, and a combination thereof. 3. The liquid pharmaceutical composition of claim 2, wherein the citrus oil is selected from the group consisting of: lemon, orange, grape, lime and grapefruit; and the fruit essence is selected from the group consisting of: apple, banana, pear, peach, strawberry, raspberry, cherry, plum, pineapple, apricot, and strawberry. 4. The liquid pharmaceutical composition of claim 1, wherein the pharmaceutical composition is free of polyhydric alcohol with 2 to 6 carbon atoms. 5. A liquid pharmaceutical composition comprising: a therapeutically effective amount of active pharmaceutical ingredient (API), at about 0.1 wt % to about 20 wt %; a preservative in the range from about 0.001 wt % to about 1 wt %; a sweetener in the range from about 0.05 wt % to about 40 wt %; a flavoring agent in the range from about 0.001 wt % to about 5 wt %; and q.s. water; wherein the liquid pharmaceutical composition has a pH from about pH 5 to about pH 8 and is stable up to 3 months at room temperature with total impurities up to 3 months being less than 0.06%, wherein the total impurities are defined as the sum of any components that are not initially present in the composition at time 0 but that are present in the composition at up to 3 months; and wherein the API consists of vigabatrin, or a pharmaceutically acceptable salt thereof. 6. The liquid pharmaceutical composition of claim 5, wherein the API is present in an amount from 5 wt % to 15 wt % in the composition; the preservative is methyl 4-hydroxy benzoate, propyl 4-hydroxy benzoate, or a combination thereof; the sweetener is maltitol, sucralose, or a combination thereof; and the flavoring agent is selected from the group consisting of: synthetic flavor oils and flavoring aromatics, natural oils, extracts from plants leaves, flowers, fruits, cinnamon oil, oil of wintergreen, peppermint oils, clove oil, bay oil, anise oil, eucalyptus, thyme oil, cedar leaf oil, oil of nutmeg, oil of sage, oil of bitter almonds, cassia oil, vanilla, citrus oil, fruit essence, and a combination thereof. 7. The liquid pharmaceutical composition of claim 6, wherein the citrus oil is selected from the group consisting of: lemon, orange, grape, lime and grapefruit; and the fruit essence is selected from the group consisting of: apple, banana, pear, peach, strawberry, raspberry, cherry, plum, pineapple, apricot, strawberry, and tutti-fruity flavor. 8. The liquid pharmaceutical composition of claim 5, wherein the pharmaceutical composition is free of polyhydric alcohol with 2 to 6 carbon atoms. 9. A liquid pharmaceutical composition comprising: a therapeutically effective amount of vigabatrin, or a pharmaceutically acceptable salt thereof, at about 0.1 wt % to about 20 wt %; a preservative in the range from about 0.001 wt % to about 1 wt %; a sweetener in the range from about 0.05 wt % to about 40 wt %; a flavoring agent in the range from about 0.001 wt % to about 5 wt %; and q.s. water, wherein the liquid pharmaceutical composition has a pH from about pH 5 to about pH 8 and is stable up to 3 months at room temperature with total impurities up to 3 months being less than 0.06%; wherein the total impurities are defined as the sum of any components that are not initially present in the composition at time 0 but that are present in the composition at up to 3 months; and with the proviso that the liquid pharmaceutical composition does not comprise any active pharmaceutical ingredient other than vigabatrin. 10. The liquid pharmaceutical composition of claim 9, wherein the vigabatrin is present in an amount from 5 wt % to 15 wt % in the composition; the preservative is methyl 4-hydroxy benzoate, propyl 4-hydroxy benzoate, or a combination thereof; the sweetener is maltitol, sucralose, or a combination thereof; and the flavoring agent is selected from the group consisting of: synthetic flavor oils and flavoring aromatics, natural oils, extracts from plants leaves, flowers, fruits, cinnamon oil, oil of wintergreen, peppermint oils, clove oil, bay oil, anise oil, eucalyptus, thyme oil, cedar leaf oil, oil of nutmeg, oil of sage, oil of bitter almonds, cassia oil, vanilla, citrus oil, fruit essence, and a combination thereof. 11. The liquid pharmaceutical composition of claim 10, wherein the citrus oil is selected from the group consisting of: lemon, orange, grape, lime and grapefruit; and the fruit essence is selected from the group consisting of: apple, banana, pear, peach, strawberry, raspberry, cherry, plum, pineapple, apricot, strawberry, and tutti-fruity flavor. 12. The liquid pharmaceutical composition of claim 9, wherein the pharmaceutical composition is free of polyhydric alcohol with 2 to 6 carbon atoms.